Table 1 Baseline characteristics of all three age groups
Patients less than 30 y.o. N = 689, N (%) | Patients 30–50 y.o., N (%) | Patients over 50 y.o. N = 136, N (%) | P value* | |
|---|---|---|---|---|
Female | 217 (26.3) | 169 (14.1) | 15 (11.0) | <0.0001 |
MSM | 268 (38.9) | 505 (24.9) | 48 (35.3) | <0.0001 |
Positive anti-HCV antibodies | 231 (33.5) | 361 (30.0) | 20 (14.7) | <0.001 |
Positive anti-HBc total antibodies | 144 (20.9) | 376 (31.3) | 60 (44.1) | <0.0001 |
Positive VDRL | 98 (14.2) | 216 (18.0) | 21 (15.4) | 0.17 |
Late presenters (CD4 <350) | 293 (42.5) | 661 (55.0) | 87 (64.0) | <0.0001 |
First cART | 0.79 | |||
PI | 491 (71.3) | 880 (73.2) | 96 (70.6) | |
NNRTI | 188 (27.3) | 303 (25.2) | 38 (27.9) | |
Any cART modification | 414 (60.1) | 771 (64.1) | 83 (61.0) | 0.20 |
Last HIV RNA <50** *opies/ml* | 543 (64.7) | 952 (79.2) | 126 (86.9) | <0.0001 |
Median (IQR) | ||||
Age in years | 26.6 (23.8–28.4) | 35.9 (32.4–40.3) | 55.7 (53–60) | – |
Haemoglobin level | 14.1 (13.0–15.1) | 14.0 (12.6–15.1) | 13.3 (11.5–14.2) | <0.0001 |
First CD4 (cells/µl) | 416 (268–570) | 317 (163–184) | 240 (80–480) | <0.0001 |
Nadir CD4 (cells/µl) | 244 (143–337) | 173 (69–274) | 166 (61–301) | <0.0001 |
Last CD4 (cells/µl) | 504 (367–673) | 476 (315–638) | 488 (356–631) | 0.012 |
First HIV RNA (log10 copies/ml)** | 4.33 (3.56–4.87) | 4.38 (3.40–4.99) | 4.43 (3.02–5.01) | 0.54 |
Follow-up time in years | 5.1 (3.2–8.3) | 6.1 (3.4–10.1) | 5.2 (3.6–9.2) | <0.0001 |
Time on cART in years | 3.4 (1.7–7.3) | 4.8 (2.4–9.0) | 4.8 (2.0–8.5) | <0.0001 |
Time on first cART in years | 1.4 (0.5–2.8) | 2.0 (0.8–3.8) | 2.0 (0.7–4.1) | <0.0001 |